Mckesson: Gemcitabine Injection
McKesson is recalling Gemcitabine Injection (a cancer medication) distributed nationwide because the drug was stored at room temperature instead of in refrigeration, which may have compromised its effectiveness. The affected product is a 1-gram vial with NDC number 0143-9341-01, distributed by Hikma. This is a Class II recall, meaning use of the product could result in serious health consequences or death.
- Recalling firm
- McKesson
- Product
- Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 0143-9341-01
- Reason
- Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment.
- Classification
- Class II
- Category
- drug recall
- Country
- United States
- Agency
- U.S. Food and Drug Administration
- Recall date
- 2026-06-10
- Status
- Ongoing
- Areas affected
- AL, AK, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, ...
- Distribution
- Nationwide within the United States
Official recall notice from U.S. Food and Drug Administration
Recall details on Nibble Recalls: https://trynibble.app/recalls/67e08fb0-fe89-4549-88a6-b29f68d79e60